Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Harvard doesn't have the HART for IPO

This article was originally published in Clinica

Executive Summary

After postponing its IPO plans last month, Harvard Bioscience has now altogether ditched the idea of floating its Harvard Apparatus Regenerative Technology (HART) subsidiary, citing poor market conditions. Instead, HART will now be spun-off to existing shareholders. Harvard initially announced plans for the IPO in March; it had been hoping to sell 1.7 million HART shares priced at $10-12 each to raise around $18.7 million (www.clinica.co.uk, 27 March 2013). However, it postponed the public offering in April (www.clinica.co.uk, 11 April 2013). HART makes synthetic organs for implantation from patients’ own stem cells, with an initial focus on the trachea. Its products are not yet approved anywhere in the world. The latest development is yet another indication of the sluggish IPO market, particularly in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel